Silexion Therapeutics Corp (NASDAQ:SLXN) Sees Large Growth in Short Interest

Silexion Therapeutics Corp (NASDAQ:SLXN) was the recipient of a large growth in short interest in July. As of July 31st, there was short interest totaling 21,284 shares, a growth of 62.6% from the July 15th total of 13,090 shares. Based on an average daily trading volume, of 111,194 shares, the short-interest ratio is currently 0.2 days. Currently, 5.3% of the shares of the stock are sold short.

Analysts Set New Price Targets

SLXN has been the subject of several recent analyst reports. Weiss Ratings reissued a “sell (e+)” rating on shares of Silexion Therapeutics in a report on Monday, June 15th. Maxim Group downgraded shares of Silexion Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Wednesday, July 29th. One analyst has rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, Silexion Therapeutics has an average rating of “Hold”.

Institutional Investors Weigh In On Silexion Therapeutics

An institutional investor recently bought a new stake in Silexion Therapeutics stock. Ancora Advisors LLC purchased a new position in shares of Silexion Therapeutics Corp (NASDAQ:SLXN) during the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 30,000 shares of the company’s stock, valued at approximately $31,000. Ancora Advisors LLC owned about 7.14% of Silexion Therapeutics at the end of the most recent quarter. 10.95% of the stock is currently owned by hedge funds and other institutional investors.

Silexion Therapeutics Stock Down 4.1%

Shares of Silexion Therapeutics stock traded down $0.02 during mid-day trading on Monday, reaching $0.40. 136,297 shares of the stock traded hands, compared to its average volume of 327,408. The business has a 50-day moving average of $2.42 and a 200 day moving average of $8.52. Silexion Therapeutics has a fifty-two week low of $0.37 and a fifty-two week high of $80.00. The stock has a market capitalization of $346,580.00, a PE ratio of -0.01 and a beta of -0.25.

Silexion Therapeutics (NASDAQ:SLXN) last released its earnings results on Friday, August 14th. The company reported ($5.17) earnings per share for the quarter, beating the consensus estimate of ($21.20) by $16.03. On average, equities research analysts expect that Silexion Therapeutics will post -45.5 EPS for the current fiscal year.

Silexion Therapeutics Company Profile

Silexion Therapeutics LTD, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform. Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for the treatment of pancreatic cancer; Prostate-LODER, which is in pre-clinical studies for the treatment of prostate cancer; and GBM-LODER that is in pre-clinical studies to target Glioblastoma Multiform, a malignant primary brain tumor.